title: Regular adult aspirin use decreases the risk of non-small cell lung cancer among women.
abstract: BACKGROUND
  Prior studies indicate that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAID) is associated with a decreased risk of non-small cell lung cancer (NSCLC); however, results have been contradictory in part because of variation in study design. Few studies have examined the use of aspirin or other NSAIDs on risk of NSCLC in women.
  
  
  METHODS
  Through a case-control study of African American and Caucasian women with and without NSCLC, we examined the relationship between use of aspirin, NSAIDs, and acetaminophen and risk of NSCLC. Risk was estimated by calculating odds ratios and 95% confidence intervals for ever/never use, duration of use, and duration of use category (never, 1-5 years, >5 years) after adjusting for major risk factors for lung cancer. Risk estimates were stratified by race, age, smoking history, and body mass index.
  
  
  RESULTS
  Every use of adult-strength aspirin was associated with a significant reduction in risk of NSCLC (odds ratio, 0.66; 95% confidence interval, 0.46-0.94). Additionally, there was a significant trend toward a reduced risk of NSCLC in adult-strength aspirin users with increasing duration of use (P(trend) = 0.02). In stratified analyses, aspirin use was associated with a significantly reduced risk of lung cancer among Caucasians and 55- to 64-year-olds. Baby aspirin and NSAID use was associated with a significant reduction in risk of NSCLC only among 65- to 74-year-olds.
  
  
  CONCLUSIONS
  Our results suggest that long-term use of adult-strength aspirin may reduce the risk of NSCLC in women.
authors.affiliation: Cancer Biology Program, Wayne State University School of Medicine, 110 East Warren Avenue, Detroit, MI 48201, USA. avandyk@med.wayne.edu
authors.forename: Alison L
authors.initials: AL
authors.lastname: Van Dyke
authors.forename: Michele L
authors.initials: ML
authors.lastname: Cote
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Prysak
authors.forename: Gina B
authors.initials: GB
authors.lastname: Claeys
authors.forename: Angie S
authors.initials: AS
authors.lastname: Wenzlaff
authors.forename: Ann G
authors.initials: AG
authors.lastname: Schwartz
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D015992:Body Mass Index; D018287:Carcinoma, Large Cell / Q000453:epidemiology / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology* / Q000473:pathology; D008875:Middle Aged; D016017:Odds Ratio; D018570:Risk Assessment; D018426:SEER Program; D014481:United States / Q000453:epidemiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000082:Acetaminophen; D001241:Aspirin